medigraphic.com
ISSN 1527-3172 (Digital)

2011, Número 3

<< Anterior Siguiente >>

MEDICC Review 2011; 13 (3)


Desarrollo farmaceútico global y acceso a medicamentos: Temas críticos de Ética y Equidad

Lage A

Idioma: Español
Referencias bibliográficas: 27
Paginas: 1-8
Archivo PDF: 226.95 Kb.


RESUMEN

El artículo presenta datos globales sobre el acceso a los productos farmacéuticos y examina las barreras subyacentes. Dos de ellas son claramente visibles: las políticas de fijación de precios, y los derechos de propiedad intelectual; otras dos son menos reconocidas: el medio regulatorio y las capacidades científicas y tecnológicas. Dos transiciones en curso infl uencian e incluso distorsionan el problema del acceso universal a los medicamentos: la transición epidemiológica hacia una carga cada vez mayor de enfermedades crónicas no transmisibles; y el creciente papel de los productos biotecnológicos (especialmente los productos inmunobiológicos) en la farmacopea. Se utilizan los ejemplos de Cuba y Brasil para explorar lo que puede y debe hacerse para solventar los aspectos comerciales, regulatorios y tecnológicos de garantizar el acceso universal a los medicamentos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Perehudoff SK. Health, Essential Medications. Human Rights & National Constitutions. Bull World Health Organ [Internet]. 2008 Jul [cited 2011 Mar 18]. Available from: http://www.who.int/ medicines/areas/human_rights/Perehudoff_report_ constitutions_2008.pdf

  2. Perehudoff SK, Laing RO, Hogerzeil HV. Access to essential medications in national constitutions. Bull World Health Organ. 2010 Nov 1;88(11):800.

  3. WHO Medications Strategy. Countries at the core 2004–2007. Geneva: World Health Organization; 2004. 12 p.

  4. Gelders S, Ewen M, Noguchi N, Laing R. Price, availability and affordability. An international comparison of chronic disease medications [Internet]. Cairo: World Health Organization; 2005 Dec [cited 2011 Mar 18]. 69 p. Available from:

  5. http://www.haiweb.org/medicinepric- es/08092008/EDB068fi nal.pdf

  6. WHO. Measuring medicine prices, availability, affordability and price components. 2nd ed. Geneva: World Health Organization; 2008. [disponible en español en: apps.who.int/medicinedocs/documents/ s16876s/s16876s.pdf—Ed.]6. Jacobzone S. IDEAS [Internet]. Connecticut: University of Connecticut. 2000 Apr. Record No. 40, Pharmaceutical Policies in OECD Countries: Reconciling Social and Industrial Goals; [cited 2011 Mar 18]; [about 2 screens]. Available from: http://ideas. repec.org/p/oec/elsaaa/40-en.html

  7. The European Parliament. Strategies for the Improvement of Global Human Health [Internet]. Strasbourg: The European Parliament; 2006 Jun 29 [cited 2011 Mar 18]. 55 p. Available from: http://www.itas.fzk.de/eng/etag/document/2006/ elde06a.pdf

  8. Newcomer LN. The Responsibility to Pay for Cancer Treatments: A Health Insurer’s View of Value. Oncologist. 2010;15 Suppl 1:32–5.

  9. Resnik DB. The Distribution of Biomedical Research Resources and International Justice. Dev World Bioeth. 2004 May;4(1):42–57.

  10. WHO. The World Health Report–Health Systems Financing: the Path to Universal Coverage [Internet]. Geneva: World Health Organization; 2010 Nov 22 [cited 2011Mar 18]. Available from: http:// www.who.int/whr/2010/whr10_en.pdf

  11. Kerry VB, Lee K. TRIPS, the Doha declaration and paragraph 6 decisions: what are the remaining steps for protecting access to medications? Global Health. 2007 May 24;3:3.

  12. WHO. Public health. Innovation and Intellectual. Property Rights. Report of the Commission on Intellectual Property Rights. Geneva: World Health Organization; 2006.

  13. Hoen E. Report of the Commission on Intellectual Property Rights, Innovation and Public Health: a call to governments. Bull World Health Organ. 2006 May;84(5):421–3.

  14. Noehrenberg E. Report of the Commission on Intellectual Property Rights, Innovation and Public Health: an industry perspective. Bull World Health Organ. 2006 May;84(5):419– 20.

  15. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability,

  16. and affordability in 36 developing and middleincome countries: a secondary analysis. Lancet. 2009 Jan 17;373(9659):240–9.

  17. Creese A, Gasman N, Mariko M. The world medications situation. Geneva: World Health Organization; 2004.

  18. Fojo T, Grady C. How Much Is Life Worth: Cetuximab, Non–Small Cell Lung Cancer, and the $440 Billion Question. J Natl Cancer Inst. 2009 Aug 5;101(15):1044–8.

  19. UNESCO. Science Report 2010 [Internet]. Paris: UNESCO Publishing; 2010 Nov 10 [cited 2011 Mar 18]. 541 p. Available from: http://unesdoc. unesco.org/images/0018/001899/189958e. pdf

  20. Mendis S, Fukino K, Cameron A, Laing R, Filipe A, Khatib O, et al. The availability and affordability of selected essential medications for chronic diseases in six low- and middle-income countries. Bull World Health Organ. 2007 Apr;85(4):279–88.

  21. Chu R, Pugatch M. Biogenerics or Biosimilars? Discussing the Present, Considering the Future. London: Stockholm Network; 2009 Oct. 31 p.

  22. EvaluatePharma® World Preview 2016 – Analysis Highlights. London: Evaluate Pharma; 2010 May. 31 p.

  23. Lage A. Connecting immunology research to public health: Cuban biotechnology. Nat Immunol. 2008 Feb;9(2):109–12.

  24. Van Puymbroeck RV. Basic Survival Needs and Access to medications–Coming to Grips with TRIPS: Conversion + Calculation. J Law Med Ethics. 2010 Fall;38(3):520–49.

  25. Lage A. Transforming Cancer Indicators Begs Bold New Strategies from Biotechnology.

  26. MEDICC Rev. 2009 Jul;11(3):8–12.

  27. Lage A, Crombet T. Control of Advanced Cancer: The Road to Chronicity. Int J Environ Res Public Health. 2011 Mar;8(3):683–97.




2020     |     www.medigraphic.com